A yeast-based tool for screening mammalian diacylglycerol acyltransferase inhibitors

Microbiologyopen. 2022 Dec;11(6):e1334. doi: 10.1002/mbo3.1334.

Abstract

Dysregulation of lipid metabolism is associated with obesity and metabolic diseases but there is also increasing evidence of a relationship between lipid body excess and cancer. Lipid body synthesis requires diacylglycerol acyltransferases (DGATs) which catalyze the last step of triacylglycerol synthesis from diacylglycerol and acyl-coenzyme A. The DGATs and in particular DGAT2, are therefore considered potential therapeutic targets for the control of these pathologies. Here, the murine and the human DGAT2 were overexpressed in the oleaginous yeast Yarrowia lipolytica deleted for all DGAT activities, to evaluate the functionality of the enzymes in this heterologous host and DGAT activity inhibitors. This work provides evidence that mammalian DGATs expressed in Y. lipolytica are a useful tool for screening chemical libraries to identify potential inhibitors or activators of these enzymes of therapeutic interest.

Keywords: DGAT; Yarrowia lipolytica; acyl-CoA:diacylglycerol acyltransferase; heterologous expression; inhibitor screening.

MeSH terms

  • Animals
  • Diacylglycerol O-Acyltransferase* / antagonists & inhibitors
  • Diacylglycerol O-Acyltransferase* / genetics
  • Enzyme Inhibitors* / pharmacology
  • Humans
  • Mice
  • Yarrowia

Substances

  • Diacylglycerol O-Acyltransferase
  • Enzyme Inhibitors